Recent Updates
Recently added Catalysts

CITY-RBP4

Phase 1

Stargardt Disease 1 | Small molecule | Other |City Therapeutics, Inc.|Trials Updated: Sep 23, 2026

CITY-RBP4 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment48

FDA Designations

No designations recorded

CITY-RBP4 clinical trials

CITY-RBP4 · 1 trial · 3 indications

Phase 1 1
NCT07836452A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 ParticipantsStargardt Disease 1
RECRUITING48 Analytics
PHASE1RECRUITING
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
Stargardt Disease 1
NCT0783645248
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs)
Through study completion, up to Day 360

To evaluate the safety and tolerability of single and multiple doses of CITY-RBP4 in healthy adults and participants with Stargardt disease Type 1 (STGD1)

Secondary Endpoints

Plasma concentrations of CITY-RBP4
Day 1 to Day 2
Urine concentrations of CITY-RBP4
Part A and B only: Day 1 to Day 2
Maximum plasma concentration (Cmax)
Day 1 to Day 2
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CITY-RBP4 in Healthy Adults (Part A)EXPERIMENTAL -
In Healthy Adults (Part A)PLACEBO_COMPARATOR -
CITY-RBP4 in Participants with STGD1 (Parts B & C)EXPERIMENTAL -
In Participants with STGD1 (Parts B & C)PLACEBO_COMPARATOR -

Interventions

NameTypeDescription
CITY-RBP4DRUGsiRNA (subcutaneous injection)
PlaceboDRUGSaline (subcutaneous injection)
Unlock Study Design Details

Eligibility Criteria

Age Range12 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Key Inclusion Criteria (Part A): 1. Willing and able to provide written informed consent form 2. Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form 3. Generally healthy on medical history, exam, labs, and ECG 4. BCVA 20/25 or better in each eye 5. Serum retinol abov...

Countries:Australia
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

City Therapeutics, Inc. (CTY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with CCompanies A to ZEvery biotech and pharma company we track